Optinose Story

<div class='circular--portrait' style='background:#4E8BFC;color: #ffffff;font-size:4em;'>OP</div>
OPTN -- USA Stock  

USD 3.49  0.02  0.57%

The basic goal of this thesis is to give institutional investors our perspective on Optinose for April. We will forecast Optinose value for institutional investors.
Published over a month ago
View all stories for Optinose | View All Stories
Our projection for Optinose (NASDAQ:OPTN) in April
This firm has a beta of 1.417. Let's try to break down what Optinose's beta means in this case. Optinose returns are very sensitive to returns on the market. As the market goes up or down, Optinose is expected to follow. The beta indicator helps investors understand whether Optinose moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if Optinose deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns.
There are currently many different techniques concerning forecasting the market as a whole as well as predicting future values of individual securities such as Optinose. Regardless of method or technology, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.

Predictive Modules for Optinose

Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Optinose's stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Optinose in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Optinose. Your research has to be compared to or analyzed against Optinose's peers to derive any actionable benefits. When done correctly, Optinose's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Optinose.

How important is Optinose's Liquidity

Optinose financial leverage refers to using borrowed capital as a funding source to finance Optinose ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Optinose financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Optinose's total debt and its cash.

How Optinose utilizes its cash?

To perform a cash flow analysis of Optinose, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Optinose is receiving and how much cash it distributes out in a given period. The Optinose cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

Purchase by Peter Miller of 11742 shares of Optinose

Legal trades by Optinose insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Optinose insider trading alert for perchase of common stock by Peter Miller, Chief Executive Officer, on 22nd of March 2021. This event was filed by Optinose Inc with SEC on 2021-03-22. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Detailed Perspective On Optinose

Optinose price slide over the last few months may encourage institutional investors to take a closer look at the company as it is trading at a share price of 3.92 on very low momentum in trading volume. The company directors and management were not very successful in positioning the company resources to exploit market volatility in February. However, diversifying your holdings with Optinose or similar stocks can still protect your portfolio during high-volatility market scenarios. The stock standard deviation of daily returns for 30 days investing horizon is currently 3.73. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Optinose partners.

Analysis of Optinose

Latest skewness is at 1.6.
As of the 3rd of March, Optinose holds the risk adjusted performance of (0.010538), and Coefficient Of Variation of (4,225). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Optinose, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We were able to interpolate nineteen technical drivers for Optinose, which can be compared to its competitors. Please check Optinose information ratio, potential upside, as well as the relationship between the Potential Upside and kurtosis to decide if Optinose is priced some-what accurately, providing market reflects its current price of 3.92 per share. Given that Optinose has jensen alpha of (0.20), we recommend you to check out Optinose's recent market performance to make sure the company can sustain itself at a future point.

Our Final Take On Optinose

Whereas many other companies in the drug manufacturers?specialty & generic industry are either recovering or due for a correction, Optinose may not be as strong as the others in terms of longer-term growth potentials. To conclude, as of the 3rd of March 2021, our concluding 30 days buy-hold-sell recommendation on the company is Sell. However, we believe Optinose is undervalued with significantly high odds of financial turmoil for the next two years.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Optinose. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com